Kinases and phosphatases are key enzymes in cell signal transduction pathways. Imbalances in these enzymes have been linked to numerous disease states ranging from cancer to diabetes to autoimmune disorders. The two isoforms (IFA and IFB) of Low Molecular Weight Protein Tyrosine Phosphatase (LMW-PTP) appear to play a role in these diseases. Pyridoxal 5′-phosphate (PLP) has been shown to act as a potent but, impractical micromolar inhibitor for both isoforms. In this study, a series of non-hydrolysable phosphonate analogs of PLP were designed, synthesized and tested against the two isoforms of LMW-PTP. Assay results demonstrated that the best inhibitor for both isoforms was compound 5 with a K_is of 1.84 μM (IFA) and 15.6 μM (IFB). The most selective inhibitor was compound 16, with a selectivity of roughly 370-fold for IFA over IFB.

激酶和磷酸酶是细胞信号转导途径中的关键酶。这些酶的失衡与多种疾病有关，从癌症到糖尿病再到自身免疫性疾病。低分子量蛋白酪氨酸磷酸酶（LMW-PTP）的两种同工型（IFA和IFB）似乎在这些疾病中起作用。吡醛5'-磷酸酯（PLP）已显示出对两种同工型均有效但不切实际的微摩尔抑制剂。在这项研究中，针对LMW-PTP的两种同工型设计，合成并测试了一系列PLP的不可水解膦酸酯类似物。分析结果表明，两种同工型的最佳抑制剂是化合物5，K分别_为1.84μM（IFA）和15.6μM（IFB）。选择性最高的抑制剂是化合物在图16中，IFA的选择性比IFB高约370倍。